BR112012018154A2 - agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular - Google Patents

agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular

Info

Publication number
BR112012018154A2
BR112012018154A2 BR112012018154A BR112012018154A BR112012018154A2 BR 112012018154 A2 BR112012018154 A2 BR 112012018154A2 BR 112012018154 A BR112012018154 A BR 112012018154A BR 112012018154 A BR112012018154 A BR 112012018154A BR 112012018154 A2 BR112012018154 A2 BR 112012018154A2
Authority
BR
Brazil
Prior art keywords
intraocular pressure
alpha
long lasting
adrenergic agonist
reducing effect
Prior art date
Application number
BR112012018154A
Other languages
English (en)
Inventor
Daniel W Gil
John E Donello
Mohammed I Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012018154(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112012018154A2 publication Critical patent/BR112012018154A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

patente de invenção: agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular. a presente invenção refere-se a um método de redução da pressão intraocular que compreende a administração de uma quantidade terapeuticanmente eficaz de uma composição farmacêutica compreendendo 4-bromo-5(2-imidazolin-2-ilamino)benzimidazol, ou um sal deste, no olho efetado de um paciente, como uma dose única, em que o olho afetado possui uma pressão intraocular menor do que a pressão intraocular de valor de referência durante pelo menos oito (8) horas.
BR112012018154A 2010-01-21 2011-01-21 agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular BR112012018154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21
PCT/US2011/022001 WO2011091225A2 (en) 2010-01-21 2011-01-21 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Publications (1)

Publication Number Publication Date
BR112012018154A2 true BR112012018154A2 (pt) 2016-04-05

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018154A BR112012018154A2 (pt) 2010-01-21 2011-01-21 agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular

Country Status (17)

Country Link
US (1) US9889088B2 (pt)
EP (1) EP2525793B1 (pt)
JP (3) JP2013518051A (pt)
KR (1) KR20120125305A (pt)
CN (1) CN102770135A (pt)
AU (1) AU2011207301A1 (pt)
BR (1) BR112012018154A2 (pt)
CA (1) CA2787573A1 (pt)
CL (1) CL2012002038A1 (pt)
CO (1) CO6592108A2 (pt)
IL (1) IL221030A0 (pt)
MX (1) MX2012008516A (pt)
RU (1) RU2012134065A (pt)
SG (1) SG182637A1 (pt)
TW (1) TW201141477A (pt)
WO (1) WO2011091225A2 (pt)
ZA (1) ZA201205470B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016073A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
CA2900671A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
US20200165687A1 (en) 2017-06-27 2020-05-28 The University Of Tokyo Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
CA2196792A1 (en) * 1994-08-04 1996-02-15 Yoon T. Jeon Novel benzimidazole derivatives
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
WO2007005177A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Alpha-2 adrenergic agonists for the treatment of pain
EP1981852A1 (en) * 2006-02-06 2008-10-22 NicOx S.A. Nitrooxy-comprising derivatives of apraclonidine and brimodnidine as al pha2 -adrenergic receptor agonists
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Also Published As

Publication number Publication date
JP6466504B2 (ja) 2019-02-06
JP2016026206A (ja) 2016-02-12
CL2012002038A1 (es) 2012-11-16
AU2011207301A1 (en) 2012-08-09
WO2011091225A2 (en) 2011-07-28
EP2525793A2 (en) 2012-11-28
JP2017125074A (ja) 2017-07-20
EP2525793B1 (en) 2018-09-05
US20110178145A1 (en) 2011-07-21
RU2012134065A (ru) 2014-02-27
TW201141477A (en) 2011-12-01
WO2011091225A3 (en) 2012-05-18
KR20120125305A (ko) 2012-11-14
CA2787573A1 (en) 2011-07-28
ZA201205470B (en) 2013-05-29
US9889088B2 (en) 2018-02-13
JP2013518051A (ja) 2013-05-20
CN102770135A (zh) 2012-11-07
IL221030A0 (en) 2012-09-24
MX2012008516A (es) 2012-10-15
SG182637A1 (en) 2012-08-30
CO6592108A2 (es) 2013-01-02

Similar Documents

Publication Publication Date Title
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
WO2008089268A3 (en) Methods and compositions for treating conditions associated with infection and/or inflammation
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112016002171A2 (pt) método, composição estéril e injetável e método para preparar uma composição estéril e injetável
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
BR112013005432A8 (pt) tratamento de doenças
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
BRPI0916885B8 (pt) composição farmacêutica
MX2009011900A (es) Curacion de herida diabetica.
BR112013028786A2 (pt) método e composição de tratamento de sementes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.